Company: BLLN
Filing Date: 2025-10-07
Form Type: S-1
Source: 0001193125-25-233697
Chunk: 199

Company: BillionToOne, Inc.
Filing Date: 2025-10-07
Form: S-1
Chunk 199
---
 smNGS platform is protected by a suite of over 50 patents and proprietary technological know-how.Our patented technologies differentiate us from our competitors and support improved quality controls, enable nimble product iteration, and drive rational assay design that allow us to build novel products with attractive gross margin. We have multiple issued patents for our core technologies and our ancillary technology in the United States and internationally. Our core patents cover various approaches to using synthetic molecules to provide accurate counting of target molecules, which is our QCT technology, as well as protecting the following technologies:

| - |     | Dilution tagging is a novel method to quantify the abundance of targeted DNA molecules across a dynamic range of many orders of magnitude. This technology enables low-cost                                 
 sequencing of cfDNA samples with rare sequences without the loss of quantitative information. For example, this can reduce sequencing costs by 10-50x for sequencing intensive applications, such as immune 
 receptor repertoire profiling and single cell RNA sequencing.                                                                                                                                               |

| - |     | Spike-in technology refers to synthetic DNA controls custom-made for each assay and added to every patient sample. These DNA controls enable the calculation of relative 
 abundance of targeted DNA molecules at a low cost.                                                                                                                       |

| - |     | qSanger technology combines spike-in technology with custom-built, proprietary signal processing and applies it to Sanger sequencing and capillary electrophoresis, bringing 
 the power of quantification to previously qualitative technologies. This approach brings NGS-level precision to easy-to-deploy                                               
 technologies and enables their use as low-cost and high-throughput diagnostic tools.                                                                                         |

Beyond these patented technologies, we have developed substantial proprietary techniques and know-howthroughout our organization that are critical to our R&D and commercial success. We protect our IP through a comprehensive strategy including patents, trademarks, copyrights, trade secrets, confidentiality agreements, and other contractual protections. For further details on our IP portfolio, including issued and pending patents, see the section titled “Intellectual property”. Engineering biology approach Our focus on quantification fundamentally transforms our R&D approach. We believe, by leveraging the precise molecular measurements enabled by our smNGS platform, we significantly reduce biological and clinical risks in our diagnostic pipeline. When designing new assays, we build mechanistic models that mathematically predict clinical performance with high confidence, transforming diagnostic development from a biology-driven trial-and-errorprocess with inherent uncertainties into an engineering challenge with clear, solvable parameters. We believe this engineering biology framework delivers exceptional capital efficiency. While many competitors invest heavily in exploratory biological research